SOURCE: OctoPlus N.V.

February 10, 2010 02:30 ET

OctoPlus Announces That Locteron Interim Phase IIb Data Have Been Accepted for Oral and Poster Presentations at International Liver Congress in April

LEIDEN, THE NETHERLANDS--(Marketwire - February 10, 2010) - OctoPlus N.V. ("OctoPlus" or "the Company") (AMS: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on has been accepted to present interim results from two ongoing Phase IIb studies with Locteron® at the 45th Liver Congress on 14 -18 April 2010 in Vienna, Austria.

Simon Sturge, CEO of OctoPlus, says: "We are delighted that the interim data for Locteron have been one of few to be selected for an oral presentation at this prestigious conference. We look forward to seeing the data and believe that this is very good news for the future of Locteron."

--  Biolex will present interim results after 12 weeks of treatment from
    its two Phase IIb studies for Locteron versus PEG-Intron® at the
    International Liver Congress in April, organised by the European
    Association for the Study of the Liver (EASL).
--  The objectives of the two Phase IIb trials are to demonstrate viral
    kinetics and response that is at least equivalent to the PEG-Intron
    control, while also achieving at least a 50% reduction in flu-like
    adverse events.
--  The data have been accepted for both oral and poster presentations.
    Under the strict rules of the conference, the results are currently
    embargoed until publication at the conference.
--  The "SELECT-2" Phase IIb study is being conducted in the United States
    and Europe in 116 treatment-naïve, genotype-1, chronic hepatitis C
    patients. Patients have been randomised into one of four dosing
    cohorts, the 320, 480 or 640 µg dose of Locteron (administered once
    every two weeks) or a control arm consisting of PEG-Intron
    (administered every week), with all patients receiving weight-based
    ribavirin. Patients will be treated for 48 weeks and will be followed
    for an additional 24 weeks to determine the sustained virologic
    response (SVR) rate. The SELECT-2 Phase IIb clinical study started in
    April 2009, and patient enrollment was completed in June 2009.
--  The second component of the planned Phase IIb trial program for
    Locteron, the "480 STUDY", is designed to provide clinical experience
    with the same Locteron configuration that is planned for use in
    Phase III trials. The 480 STUDY was also initiated last year, is being
    conducted in Europe and Israel, and will include at least 72
    treatment-naïve hepatitis C patients with the genotype-1 variant of the
--  Locteron's expected product profile was tested by Biolex in extensive
    market research in the first half of 2009, and the research results
    suggested that the potential tolerability and dosing convenience
    advantages of Locteron support a substantial commercial opportunity. It
    is estimated that worldwide sales of interferon products for the
    treatment of hepatitis C will approach US$6 billion by 2016.

Under its agreement with Biolex, OctoPlus is eligible to:

-- Milestone payments which may exceed US$ 135 million
-- Royalties on net product sales.
-- An equity stake in Biolex.

About Locteron

Locteron is a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. Locteron combines OctoPlus' controlled release drug delivery technology PolyActive® with Biolex' interferon alpha and is the most advanced product in clinical development incorporating one of OctoPlus' proprietary drug delivery technologies. OctoPlus licensed its commercial rights to Locteron exclusively to Biolex in October 2008.

About OctoPlus

OctoPlus is a drug delivery service company committed to the creation of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics, other drugs, and vaccines on behalf of its clients.

The clinically most advanced product incorporating our technology is Biolex Therapeutics' lead product Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and is currently in Phase IIb clinical studies.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.

Click here for the press release in PDF:

Contact Information

  • For further information, please contact:
    Rianne Roukema
    Corporate Communications
    telephone number +31 (71) 524 1071
    or send an e-mail to Investor Relations at